NCT04122872 GISAR German Interdisciplinary Sarcoma Registry
| NCT ID | NCT04122872 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
| Condition | Sarcoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 9,000 participants |
| Start Date | 2018-11-29 |
| Primary Completion | 2038-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 9,000 participants in total. It began in 2018-11-29 with a primary completion date of 2038-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
GISAR has an open and modular setup. It is sought to include as many German sarcoma and CS patients (i.e. sarcoma and CS patients treated in Germany) in the registry as possible. A basic data set should be collected on every included patient). In order to adress specific scientific questions, additionally detailed data can be collected in defined patient groups (e.g. effectiveness / adverse effects of systemic therapies in defined situations) within the context of sub-project add-on modules. This data collection can be prospective or retrospective depending on the sub-project
Eligibility Criteria
Inclusion Criteria: * Histological verified bone or soft tissue sarcomas including bone and soft tissue tumors with borderline histological results or with unclear histological dignity like giant cell tumors of the bone (GCTB), desmoid tumors, atypical lipomatous tumors etc. - independent of therapy form and therapy line - or Histological verified sarcomatoid carcinomas/ carcinosarcomas: tumors with histological, cytological, or molecular properties of both epithelial tumors ("carcinoma") and mesenchymal tumors ("sarcoma") - independent of therapy form and therapy line. * Signed informed consent form or equivalent (s. chapter 10) * Age ≥18 years Exclusion Criteria: * none
Contact & Investigator
Salah-Eddin Al-Batran, Prof. Dr
STUDY DIRECTOR
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Frequently Asked Questions
Who can join the NCT04122872 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04122872 currently recruiting?
Yes, NCT04122872 is actively recruiting participants. Contact the research team at daniel.pink@helios-gesundheit.de for enrollment information.
Where is the NCT04122872 trial being conducted?
This trial is being conducted at Tübingen, Germany, Erlangen, Germany, Bad Saarow, Germany, Berlin, Germany and 11 additional locations.
Who is sponsoring the NCT04122872 clinical trial?
NCT04122872 is sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. The principal investigator is Salah-Eddin Al-Batran, Prof. Dr at Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. The trial plans to enroll 9,000 participants.